Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks News

Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax

The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax

Zacks Equity Research

Moderna (MRNA) Stock Moves -0.35%: What You Should Know

Moderna (MRNA) closed the most recent trading day at $47.88, moving -0.35% from the previous trading session.

Zacks Equity Research

3 Stocks to Benefit From Race to Develop Coronavirus Vaccines

Pharmaceutical companies and scientists are relentlessly working on developing coronavirus vaccines and the progress in trails has helped stocks to rally.

Zacks Equity Research

Pfizer/BioNTech to Begin Coronavirus Vaccine Study in Germany

Pfizer (PFE) and BioNTech receive approval from regulatory authority in Germany to start an early-stage clinical study to evaluate their mRNA-based vaccine candidates for COVID-19.

Zacks Equity Research

Vaxart Up on Pre-Clinical Data on Coronavirus Vaccine Candidates

Vaxart's (VXRT) several COVID-19 vaccine candidates generate immune responses in pre-clinical studies. Stock rises.

Zacks Equity Research

Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

Sweta Killa headshot

Coronavirus Makes Biotech ETFs Red Hot

The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.

Zacks Equity Research

Company News for Apr 20, 2020

Companies In The News Are: TROX, MRNA, PLNT and PG

Zacks Equity Research

The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly

The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly

Ritujay Ghosh headshot

Gilead Increases Enrollment Target, Pharma Rally Continues

Substantial progress has been made over the past few weeks with pharmaceutical companies speeding up development of coronavirus vaccines.